Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2023 |
|---|---|
| Revenue | — |
| R&D expense | $2.4M |
| Operating income | −$9.5M |
| Net income | −$8.6M |
| Cash & equivalents | $4.1M |
| Total debt | $274,000 |
| Operating cash flow | −$8.6M |
| Free cash flow | −$8.6M |
Company profile
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.